Buscar en
Neurología (English Edition)
Toda la web
Inicio Neurología (English Edition) “Code stroke” activation in a patient with an external ventricular assist de...
Journal Information
Vol. 34. Issue 1.
Pages 64-65 (January - February 2019)
Vol. 34. Issue 1.
Pages 64-65 (January - February 2019)
Letter to the Editor
Open Access
“Code stroke” activation in a patient with an external ventricular assist device
Código ictus en paciente portador de dispositivo de asistencia ventricular externa
Visits
2061
A.A. Urbanos Núñeza,
Corresponding author
urbanos.nunez@gmail.com

Corresponding author.
, D. Barragán Martíneza, M.H. Torregrosa Martínezb, A. Martínez Salioa
a Servicio de Neurología, Hospital Universitario 12 de Octubre, Madrid, Spain
b Servicio de Neurología, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain
This item has received

Under a Creative Commons license
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text
Dear Editor,

External ventricular assist devices (EVAD) have been available since 2002 as an alternative treatment or bridging therapy to heart transplant for patients with severe systolic dysfunction in situations of advanced refractory (stage D) heart failure (HF). The devices constitute a long-term, percutaneous, mechanical circulatory support comprising an electrically-powered pump driving blood from the left ventricle to the ascending aorta though a system of cannulas.1,2 First-generation devices produced a pulsatile flow, similar to physiological haemodynamics. However, a subsequent study revealed greater survival and a lower rate of complications with continuous-flow devices3; therefore, the latter are most frequently used today.

Stroke is one the most frequent complications associated with these devices, with an estimated annual incidence rate of 0.19.4,5 The implication of this is that in the coming years, these devices will be an infrequent but growing reason for code stroke (CS) activation. However, no studies have addressed the treatment of hyperacute stroke in these patients. We report our experience with the management of CS in a patient with an EVAD.

Our patient was a 54-year-old man with a personal history of arterial hypertension, dyslipidaemia, and atrial fibrillation treated with cardioversion. An EVAD (initially an EXCOR® Berlin Heart device, replaced by continuous-flow Levitronix® CentriMag® VAD due to thrombosis in the first device) had been inserted as bridging therapy to the heart transplant (HT) due to ischaemic HF. He had been admitted to another hospital for 27 days due to a spontaneous right parietal occipital haematoma presenting with headache, vomiting, and left homonymous hemianopsia; the patient progressed favourably, becoming asymptomatic (modified Rankin Scale: 1-2). He was receiving anticoagulant medication (perfusion with bemiparin; partial thromboplastin time of 54s) and antiplatelet treatment with acetylsalicylic acid and clopidogrel.

The patient suffered a left-hemisphere stroke, presenting altered level of consciousness, global aphasia, left-sided deviation of the head and eyes, right-sided homonymous hemianopsia, facial paresis, hemiplegia, and brachiocrural hemianaesthesia (NIHSS score: 21). The baseline brain computed tomography scan revealed no sign of acute ischaemia (ASPECTS score: 10); the angiography study showed occlusion of the M1 segment of the left middle cerebral artery (MCA) with limited leptomeningeal collateral circulation (LCC). Since systemic fibrinolysis was contraindicated due to a recent intracranial haemorrhage and active anticoagulation, the patient was transferred to our hospital to receive neurointerventional treatment. Complete reperfusion of the vascular tree (TICI grade 3) was achieved 3hours and 45minutes after symptom onset. The procedure was completed with no complications.

Despite the arteriographic success, infarction of the left MCA with areas of haemorrhagic transformation was confirmed at 24hours. The patient progressed poorly. His level of consciousness did not improve, so he remained intubated; he presented new bihemispheric ischaemic lesions, fever, and haemodynamic instability. As the lesions were irreversible, CT was ultimately ruled out and treatment was limited. The patient died 11 days after the stroke. No echocardiography or other diagnostic tests were performed to rule out intracavitary thrombi or device thrombosis.

Our case is interesting as it underscores the lack of scientific evidence regarding the management of acute stroke in patients with EVADs. Based on isolated clinical cases6–9 and expert opinion, some authors recommend proceeding in the same way as with patients without this type of devices5; all these patients, with some exceptions, receive anticoagulant treatment and are therefore not eligible for intravenous fibrinolysis. Our patient's clinical outcome was not as favourable as expected, considering how quickly revascularisation was achieved.

After analysing the pathophysiology of the case, we believe that haemodynamics probably played a fundamental role in treatment failure. Some authors10 have highlighted that if arterial flow is interrupted, the fluid shear stress caused by the increased mechanical pressure of the bloodstream on the endothelium of collateral vessels would activate the preexisting LCC, in a process known as arteriogenesis. Moderately elevated systolic blood pressure (170-190mmHg) at the time of stroke has been clinically demonstrated to maintain a more efficient LCC, which was correlated with a better functional prognosis at 3 months,11 and translated into a recommendation to avoid an excessive decrease of arterial pressure during acute stroke.12 Our hypothesis is that both the patient's heart failure and the fact that the EVAD maintained a continuous flow at 60-70mmHg would have limited his hypertensive response, and consequently the capacity to maintain permeability of the LCC at the time of ischaemia.

This case highlights the need to expand our knowledge on the management of stroke in patients with EVADs. Confirming our hypothesis would require collateral circulation models of both haemodynamic situations (continuous and pulsatile flow), as well as prospective studies. If our hypothesis is correct, we may expect poorer neurological prognosis of stroke in patients with continuous-flow EVADs than in those with pulsatile-flow devices; the therapeutic window for brain reperfusion may also be shorter due to early failure of the compensatory mechanisms.

References
[1]
D.J. Goldstein, M.C. Oz, E.A. Rose.
Implantable left ventricular assist devices.
N Engl J Med, 339 (1998), pp. 1522-1533
[2]
D. Mancini, P.C. Colombo.
Left ventricular assist devices: a rapidly evolving alternative to transplant.
J Am Coll Cardiol, 65 (2015), pp. 2542-2555
[3]
M.S. Slaughter, J.G. Rogers, C.A. Milano, S.D. Russell, J.V. Conte, D. Feldman, et al.
Advanced heart failure treated with continuous-flow left ventricular assist device.
N Engl J Med, 361 (2009), pp. 2241-2251
[4]
R.M. Lazar, P.A. Shapiro, B.E. Jaski, M.K. Parides, R.C. Bourge, J.T. Watson, et al.
Neurological events during long-term mechanical circulatory support for heart failure: The Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) experience.
Circulation, 109 (2004), pp. 2423-2427
[5]
J.Z. Willey, R.T. Demmer, H. Takayama, P.C. Colombo, R.M. Lazar.
Cerebrovascular disease in the era of left ventricular assist devices with continuous flow: risk factors, diagnosis, and treatment.
J Heart Lung Transplant, 33 (2014), pp. 878-887
[6]
I. Alnaami, H. Buchholz, R. Ashforth, T. Yeo, T. Kotylak, M. Alaklabi, et al.
Successful use of Solitaire FR for stroke in a pediatric ventricular assist device patient.
Ann Thorac Surg, 96 (2013), pp. e65-e67
[7]
E. Rhee, R. Hurst, B. Pukenas, R. Ichord, A.M. Cahill, J. Rossano, et al.
Mechanical embolectomy for ischemic stroke in a pediatric ventricular assist device patient.
Pediatr Transplant, 18 (2014), pp. E88-E92
[8]
R.P. From, D. Hasan, M.T. Froehler, J.L. Goerbig-Campbell.
Stroke and left ventricular assist device (LVAD).
OJAnes, 3 (2013), pp. 51-56
[9]
F. Al-Mufti, A. Bauerschmidt, J. Claassen, P.M. Meyers, P.C. Colombo, J.Z. Willey.
Neuroendovascular interventions for acute ischemic strokes in patients supported with left ventricular assist devices: a single-center case series and review of the literature.
World Neurosurg, 88 (2016), pp. 199-204
[10]
Y. Nishijima, Y. Akamatsu, P.R. Weinstein, J. Liu.
Collaterals: implications in cerebral ischemic diseases and therapeutic interventions.
Brain Res, 1623 (2015), pp. 18-29
[11]
H. Rusanen, J.T. Saarinen, N. Sillanpää.
The association of blood pressure and collateral circulation in hyperacute ischemic stroke patients treated with intravenous thrombolysis.
Cerebrovasc Dis, 39 (2015), pp. 130-137
[12]
E.C. Jauch, J.L. Saver, H.P. Adams, A. Bruno, J.J.B. Connors, B.M. Demaerschalk, et al.
Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.

Please cite this article as: Urbanos Núñez AA, Barragán Martínez D, Torregrosa Martínez MH, Martínez Salio A. Código ictus en paciente portador de dispositivo de asistencia ventricular externa. Neurología. 2019;34:64–65.

This study was presented in poster format at the 13th Annual Meeting of the Neurological Association of Madrid.

Copyright © 2017. Sociedad Española de Neurología
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.nrleng.2020.07.023
No mostrar más